Semaglutide in Auto-HSCT
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: inflammation
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; BMI ≥18 required; non-obese participants included; conditions: Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity
- Interventions
- Semaglutide Pen Injector [Ozempic]; Placebo
- Conditions
- Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity
- Phase and size
- Phase 2 · 40 participants
- Dates
- Start 2024-08-12
Primary completion 2026-12-31 - Sponsor
- Klaus Gottlob Müller (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- gastrointestinal mucositis severityfrom day of stem cell infusion (day 0) to week +3
02Eligibility
Who can take part
Inclusion Criteria: * Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma or follicular lymphoma * Age ≥ 18 years * BMI ≥ 18.5 * ECOG performance status\* ≤ 2 * Literate in Danish and/or English Exclusion Criteria: * Diabetes * Inflammatory bowel disease * Previous or current gastrointestinal malignancy * Personal or family history of medullary thyroid carcinoma or MEN syndrome * Genetic disorders with defective tissue repair (e.g., Fanconi anaemia) * History of pancreatitis (acute or chronic) * Renal impairment measured as eGFR value of \< 30 ml/min/1.73 m2 * Impaired liver function, defined as alanine aminotransferase ≥ 2.5 times upper normal limit at screening * Known or suspected hypersensitivity to semaglutide or other GLP-1RA * Pregnant or nursing females
03Change log
Registry changes
No changes recorded since the trial was added.